Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report

Sobas, Marta; Wróbel, Tomasz; Zduniak, Krzysztof; Podolak-Dawidziak, Maria; Rybka, Justyna; Biedroń, Monika; Sawicki, Mateusz; Dybko, Jarosław; Kuliczkowski, Kazimierz

doi:10.1155/2017/3725089

Cited by 6 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ET and ITP are different blood diseases with PLT counts at opposite extremes. So far, only 2 previous reports described ET following ITP [7] , [8] . Hereby we describe a third case of ET diagnosed 13 years after ITP diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Caocci

Atzeni

Usai

et al. 2018

Leukemia Research Reports

View full text Add to dashboard Cite

JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only 2 reports described ET following ITP. For the first time we analyzed in a patient the JAK2V617F allele burden at ITP onset occurred 13 years before the ET diagnosis and found the presence of a small clone JAK2V617F positive clone (3%) raised to 27% in the following years. The association of ET and ITP could suggest similar pathogenetic mechanisms that should be further investigated.

show abstract

Section: Introductionmentioning

confidence: 99%

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Caocci

Atzeni

Usai

et al. 2018

Leukemia Research Reports

View full text Add to dashboard Cite

show abstract

“…We present a case of ITP with subsequent development of JAK2(V617F)positive ET, after four years of follow-up. There are only a few cases reported of ET in patients with a prior history of ITP [9,10]. The pathophysiology relating to these two conditions is incompletely understood, however, JAK2(V617F) mutation has been found in all the cases reported.…”

Section: Discussionmentioning

confidence: 99%

“…The sequential occurrence of two different types of platelet disorder as ITP and ET is rarely reported in the literature [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Immune thrombocytopenic purpura with subsequent development of JAK2 V617F-positive essential thrombocythemia: Case Report

Hurtado-Castillo¹,

Flaherty²,

Jrada³

2021

Arch Hematol Case Rep Rev

View full text Add to dashboard Cite

The sequential occurrence of Immune Thrombocytopenic Purpura (ITP) and Essential Thrombocythemia (ET) has been reported in the literature on a few occasions, as these are two hematologic disorders with distinct etiologies and patients usually have contrasting clinical presentations. Our case highlights the sequential occurrence of ITP, followed by Janus kinase 2 (JAK2) (V617F)-positive ET in a 64-year-old white woman, after four years of follow-up. The pathophysiology relating to these two conditions is incompletely understood, however, JAK2(V617F) mutation has been found in all the cases reported. Early identifi cation of JAK2(V617F) mutation in a patient with a past medical history of ITP and presenting with thrombocytosis, may lead to a prompt diagnosis of ET and timely treatment initiation.

show abstract

“…We have identified in the literature five cases of ITP with subsequent development of ET (group 1, Table 1) [1][2][3][4][5]. ET was diagnosed several years after ITP (3.5, 4, 7, 13, and 21 years, respectively).…”

Section: Review Of Cases Published In a Literaturementioning

confidence: 99%

“…In the past few years several cases of immune thrombocytopenia (ITP) which developed into essential thrombocythemia (ET), and in some instances, cases with ET followed by ITP have been reported [1][2][3][4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar—Cases Series and a Review of the Literature

Sobas

Podolak-Dawidziak

Lewandowski

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

This article collects several published cases in which immune thrombocytopenic purpura (ITP) is followed by essential thrombocythemia (ET) and vice versa. This surprising clinical condition is possible, but very rare and difficult to diagnose and manage. We have made an attempt to analyse the possible causes of the sequential appearance of ITP and ET taking into consideration the following: alteration of the thrombopoietin (TPO) receptor, the role of autoimmunity and inflammation, and cytokine modulation. A better understanding of these interactions may provide opportunities to determine predisposing factors and aid in finding new treatment modalities both for ITP and ET patients.

show abstract

Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report

Cited by 6 publications

References 14 publications

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Immune thrombocytopenic purpura with subsequent development of JAK2 V617F-positive essential thrombocythemia: Case Report

Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar—Cases Series and a Review of the Literature

Contact Info

Product

Resources

About